PubRank

Amy B Heimberger

Author PubWeight™ 67.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010 6.30
2 Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007 3.07
3 Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 2010 2.71
4 The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006 2.53
5 Altered adenosine-to-inosine RNA editing in human cancer. Genome Res 2007 2.38
6 Retracted Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010 2.24
7 Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012 2.19
8 Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res 2011 2.15
9 Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol 2012 2.02
10 Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2010 2.00
11 Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2010 1.99
12 Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006 1.91
13 A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007 1.91
14 A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 2008 1.80
15 Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2007 1.70
16 An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009 1.67
17 The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 2008 1.62
18 Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008 1.47
19 miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 2013 1.46
20 EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009 1.40
21 Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One 2009 1.19
22 Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 2011 1.17
23 Awake craniotomy for brain tumors near eloquent cortex: correlation of intraoperative cortical mapping with neurological outcomes in 309 consecutive patients. Neurosurgery 2009 1.16
24 Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol 2012 1.16
25 Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res 2010 1.15
26 Innate immune functions of microglia isolated from human glioma patients. J Transl Med 2006 1.12
27 Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res 2010 1.09
28 A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 2008 1.06
29 Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget 2012 1.00
30 The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am 2010 0.98
31 Immune therapeutic targeting of glioma cancer stem cells. Target Oncol 2010 0.95
32 BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother 2013 0.92
33 Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther 2005 0.91
34 Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am 2010 0.87
35 Topotecan enhances immune clearance of gliomas. Cancer Immunol Immunother 2008 0.86
36 Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2005 0.85
37 The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer 2011 0.83
38 The role of STAT3 in tumor-mediated immune suppression. J Neurooncol 2015 0.82
39 The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget 2012 0.81
40 Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res 2007 0.81
41 Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis. Int J Cancer 2014 0.80
42 yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med 2009 0.79
43 Central nervous system cancers. J Natl Compr Canc Netw 2008 0.79
44 miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clin Investig (Lond) 2011 0.78
45 Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. J Immunother 2016 0.76